Ray Dogum
Ray Dogum is the Chief Editor of Drug Discovery Online, where he curates and leads editorial content focused on the earliest phases of drug development—from target identification and hit discovery to preclinical validation. With a background in chemical engineering and master's degrees in business and information systems from Boston University’s Questrom School of Business, Ray brings a cross-disciplinary perspective to the future of therapeutic innovation.
Ray’s career has spanned the cutting edge of healthcare and technology. At Amwell, he implemented telehealth solutions integrating medical devices and digital platforms across major US health systems. At Vibe Bio, he launched a biotech-focused podcast and newsletter, driving engagement for the company’s AI-powered pipeline analysis platform. He’s also consulted with senior pharma executives on decentralized ledger technology and led a proof-of-concept to streamline patient-centric clinical trial pre-screening.
Earlier in his career, Ray helped launch and manage a stem cell biology lab at MIT’s Koch Institute, where he supported research into the role of diet in aging and metabolic disease. Ray is also the creator and host of Health Unchained, a podcast exploring how blockchain, AI, and frontier technologies are transforming healthcare. Through in-depth interviews with researchers, entrepreneurs, and investors, he has built a resource that bridges the gap between emerging tech and real-world healthcare applications.
Passionate about enabling collaboration across disciplines, Ray is committed to helping scientists, startups, and innovators tell the stories behind their breakthroughs, shaping the conversation at the intersection of science, technology, and human health. You can often find Ray at local Boston events, staying close to the pulse on the latest discoveries and connecting with the vibrant biotech community.
Connect with Ray Dogum on LinkedIn: https://www.linkedin.com/in/raydogum/
ARTICLES BY RAY DOGUM
-
![quantum entanglement and non-local connections in quantum physics-GettyImages-2216950680]( "Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery")
Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery1/23/2026On January 26th, 2026 as we celebrate this centennial milestone of Schrödinger’s Equation, it’s worth asking: What does quantum mechanics mean for drug discovery and biomolecular simulations?
-
![GettyImages-2246207235]( "Annual Reflections And Predictions From The Editors' Roundtable")
Annual Reflections And Predictions From The Editors' Roundtable1/6/2026Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.
-
![Stop Fentanyl-GettyImages-2198578451]( "The Unlikely Weapon Against Fentanyl: Your Immune System")
The Unlikely Weapon Against Fentanyl: Your Immune System12/23/2025ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs).
-
![advancement innovation-GettyImages-2218939025]( "2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026")
2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 202612/15/2025Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.
-
![Cancer detection-GettyImages-1477214805]( "GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers")
GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers11/24/2025General Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.
-
![20251118_100400]( "From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025")
From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 202511/20/2025Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.
-
![Science and lab equipment-GettyImages-2168387231]( "Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs")
Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs11/13/2025According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.
-
![GettyImages-2207965610]( "OpenFold3 Released: Redefining The Limits Of Protein Prediction Models")
OpenFold3 Released: Redefining The Limits Of Protein Prediction Models11/4/2025OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.
-
![IMG_20251003_150653_854 copy]( "Video Spotlight: Where Science Meets Magic with MIT Institute Professor Robert S. Langer")
Video Spotlight: Where Science Meets Magic with MIT Institute Professor Robert S. Langer10/29/2025Drug Discovery Online interviews MIT’s Bob Langer on biomedical innovation, personalized medicine, longevity, and entrepreneurship—highlighting his journey, lab impact, and personal discipline.
-
![Government Shutdown-GettyImages-1095055188]( "Discovery On Hold: How Shutdowns Stall Science And Shake Trust")
Discovery On Hold: How Shutdowns Stall Science And Shake Trust10/10/2025When the federal government shuts down and appropriations lapse, the ripple effects reach deep into early drug development efforts. FDA slows regulatory intake, NIH freezes grant reviews and awards, clinical trials are disrupted, and talent pipelines tighten as student and work visas remain in limbo.
